Viking Therapeutics Inc
For the period ended Mar 31, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 25, 2024
VKTX$26.84+4.1%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Viking Therapeutics, Inc. | ||
| Date: April 24, 2024 | By: | /s/ Brian Lian, Ph.D. |
|---|---|---|
| Brian Lian, Ph.D. | ||
| President, Chief Executive Officer and Director(Principal Executive Officer) | ||
| Date: April 24, 2024 | By: | /s/ Greg Zante |
| Greg Zante | ||
| Chief Financial Officer (Principal Accounting and Financial Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.